Department of Health and Human Services
200 Independence Avenue, S.W.
Washington
D.C.
20201
United States
Tel: 877-696-6775
Website: http://www.hhs.gov/
Email: hhsmail@os.dhhs.gov
113 articles with Department of Health and Human Services
-
The inclusion of the list price is part of an effort from the administration to lower the cost of prescription drugs. The industry's lobbying arm believes the inclusion will be confusing to patients.
-
Emergency Physicians: HHS Conscience Rule Puts Patient Safety At Risk
5/3/2019
A final rule issued this week by the Department of Health and Human Services expands "conscience protections" for providers who refuse to administer certain types of care based on religious belief or moral conviction.
-
Thursday Chicago Court Proceedings Center on Controversial HHS Protections of Human Experiments
5/1/2019
Are patients being adequately protected when they are involved in studies of new medical therapies and devices?
-
HHS And The American Society Of Nephrology Award Kidneyx Redesign Dialysis Phase 1 Winners
4/29/2019
The U.S. Department of Health and Human Services Office of the Chief Technology Officer and the American Society of Nephrology have selected 15 winning teams for Phase 1 of the KidneyX Redesign Dialysis prize competition.
-
Statement by Douglas Throckmorton, M.D., Deputy Center Director for Regulatory Programs in FDA's Center for Drug Evaluation and Research, on new opioid analgesic labeling changes to give providers better information
4/9/2019
As the Department of Health and Human Services continues to make progress against the opioid crisis, the FDA remains focused on striking the right balance between reducing the rate of new addiction by decreasing excessive exposure to opioids through rational prescribing, while still enabling appropriate access to treatment for patients living with serious pain.
-
The White House budget proposal released earlier this week that slashed spending on the National Institutes of Health and Medicare programs has put members of the administration, including Health and Human Services Secretary Alex Azar on the defensive.
-
USDA and FDA Announce a Formal Agreement to Regulate Cell-Cultured Food Products from Cell Lines of Livestock and Poultry
3/7/2019
The U.S. Department of Agriculture's Food Safety and Inspection Service and the U.S. Department of Health and Human Services' Food and Drug Administration announced a formal agreement to jointly oversee the production of human food products derived from the cells of livestock and poultry.
-
HHS Secretary Azar on Transforming Kidney Care
2/28/2019
Secretary of Health and Human Services to speak to kidney patients and families at the Kidney Patient Summit
-
Empatica Partners With DRIVe to Develop Smart Watch That Predicts Lung Infections Before Symptoms Appear
2/19/2019
Empatica is proud to announce its partnership with the U.S. Government's BARDA Division of Research, Innovation and Ventures, under the Department of Health and Human Services, to collaborate on the development of a new smart watch which will alert users when they are developing a serious respiratory infection, before any symptoms appear.
-
GeoVax Issues Open Letter to HHS Secretary Alex Azar
2/14/2019
GeoVax Labs, Inc., a biotechnology company developing human vaccines, today published an open letter to U.S. Department of Health and Human Services Secretary Alex Azar in response to the HHS initiative “Ending the HIV Epidemic: A Plan for America.”
-
After Health and Human Services Secretary Alex Azar, a former executive with Eli Lilly, unveiled a pricing reform that would allow pharma companies to end the rebate system and pass those savings directly to consumers, leaders from across the pharma industry are offering early support for the pro...
-
Last week HHS floated a plan that would allow companies to pass rebates of 26 to 30 percent of a drug’s list price directly to patients in order to be reflected in what consumers pay at the pharmacy counter.
-
Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.
-
The plan is aimed at providing new transparency to the prescription drug market and removing the veil of hidden rebates conducted between companies and pharmacy benefits managers.
-
The U.S. Senate Finance Committee and the House Oversight Committee started hearings on Tuesday, January 29, focused on dealing with high drug prices.
-
U.S. federal lawmakers are discussing various legislative plans that could lower the out-of-pocket expenses many Americans pay for their medications. The plans are coming from both chambers of Congress and with a divided government, lines in the sand will likely be drawn.
-
In theory, the U.S. Food and Drug Administration (FDA) is tasked with overseeing the safety of food and drugs in the U.S. based on science, not politics. That doesn’t always work.
-
In a December 17, Washington Post op-ed, Senator Elizabeth Warren (D-MA), proposed The Affordable Drug Manufacturing Act, which would allow the Department of Health and Human Services (HHS) to manufacture or contract out the manufacture of generic drugs.
-
7 Biotech Trends to Look Out for in 2019
12/26/2018
As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle. -
The FDA has been looking for ways to increase access to naloxone, an opioid overdose reversal drug, and the new guidelines are part of that effort.